Carbavance meropenem/vaborbactam: Completed Phase III enrollment

The Medicines Co. completed enrollment of about 550 patients in the double-blind, double-dummy, international Phase III TANGO 1

Read the full 180 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE